Cingulate (CING) to Release Quarterly Earnings on Thursday

Cingulate (NASDAQ:CING) is expected to be releasing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Cingulate to post earnings of ($0.53) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Cingulate (NASDAQ:CING) last posted its quarterly earnings results on Wednesday, March 18th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.28). On average, analysts expect Cingulate to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cingulate Stock Performance

Cingulate stock opened at $5.33 on Thursday. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $65.30 million, a P/E ratio of -1.23 and a beta of -0.81. The stock’s 50 day moving average is $6.46 and its 200 day moving average is $5.24. Cingulate has a twelve month low of $3.20 and a twelve month high of $11.89.

Insider Buying and Selling at Cingulate

In other news, Director Peter J. Werth purchased 19,455 shares of the stock in a transaction dated Friday, February 6th. The shares were purchased at an average cost of $5.04 per share, with a total value of $98,053.20. Following the acquisition, the director directly owned 117,449 shares of the company’s stock, valued at $591,942.96. This represents a 19.85% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Shane J. Schaffer purchased 6,809 shares of the stock in a transaction dated Friday, February 6th. The shares were purchased at an average cost of $5.04 per share, for a total transaction of $34,317.36. Following the completion of the acquisition, the chief executive officer directly owned 10,175 shares in the company, valued at approximately $51,282. This trade represents a 202.29% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 33,074 shares of company stock worth $166,693 over the last three months. Insiders own 4.33% of the company’s stock.

Hedge Funds Weigh In On Cingulate

Several hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new position in Cingulate in the 2nd quarter worth $45,000. Bank of America Corp DE raised its holdings in Cingulate by 283.1% in the 2nd quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock worth $31,000 after purchasing an additional 5,543 shares during the period. Geode Capital Management LLC raised its holdings in Cingulate by 43.9% in the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock worth $265,000 after purchasing an additional 18,629 shares during the period. DRW Securities LLC bought a new position in Cingulate in the 4th quarter worth $255,000. Finally, Kestra Advisory Services LLC raised its holdings in Cingulate by 29.8% in the 4th quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company’s stock worth $529,000 after purchasing an additional 27,979 shares during the period. 41.31% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on CING. Roth Mkm cut their target price on Cingulate from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cingulate in a research note on Monday, April 20th. Finally, Ascendiant Capital Markets cut their target price on Cingulate from $58.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, April 8th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Cingulate currently has an average rating of “Hold” and an average price target of $34.50.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.